Satellos Bioscience Inc. Common Stock (MSLE) is a publicly traded the market company. As of July 8, 2026, MSLE trades at $9.37 with a market cap of $172.27M and a P/E ratio of 0.00. MSLE moved +15.10% today. Year to date, MSLE is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $5.44 to $13.39. Analyst consensus is strong buy with an average price target of $21.48. Rallies surfaces MSLE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Satellos Shows 3.7% Fat Fraction Drop, 34% Effort Gain and 38% CK Reduction: Satellos’ six-month TRAILHEAD data in four adults with Duchenne muscular dystrophy showed a mean 3.7% decline in muscle fat fraction (from 49.7% to 46.0%) and a 34% increase in upper limb effort (from 16.1 to 21.6 joules/kg). Mean creatine kinase levels fell by 38% and near-doubled handgrip strength remained stable, with no serious adverse events.
| Metric | Value |
|---|---|
| Price | $9.37 |
| Market Cap | $172.27M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.39 |
| 52-Week Low | $5.44 |
| Volume | 193.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover MSLE: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.48.